Special Issue "2-[18F]-FDG PET/CT in Oncology: New Evidences and Future Perspectives"
Deadline for manuscript submissions: closed (15 August 2021).
Interests: PET/CT; nuclear medicine; lymphoma; thyroid cancer
Cancer is one of the leading causes of death worldwide. Accurate diagnosis, staging and restaging are essential for the optimal management and therapeutic choice for oncological patients.
In this scenario, the potential usefulness of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (2-[18F]-FDG PET/CT) is well demonstrated in different oncological diseases and for different purposes (such as staging, treatment response evaluation, restaging). 18F-FDG is an analogue of glucose and provides valuable functional information based on the increased glucose uptake and glycolysis of cancer cells and depicts metabolic abnormalities before morphological alterations occur. PET/CT is a hybrid tool that allows the acquisition of both morphological and functional data in the same imaging helping in the definition of disease status. However, there are some limitations and areas of uncertainty, mainly regarding the lack of specificity of 18F-FDG uptake and the variable FDG-avidity of some cancers.
Nowadays other more specific radiotracers (like choline, PSMA, DOTA-peptides) and new scanners (PET/MRI) have been developed with promising evidence; however, the role of 2-[18F]-FDG PET/CT remains fundamental and widespread. Moreover, several areas of interest are yet to be widely investigated.
This Special Issue will highlight the role of 2-[18F]-FDG PET/CT for the study of oncological diseases. We encourage authors to submit both preclinical and clinical studies in the field. Clinical studies may include systematic reviews, retrospective studies, and prospective studies emphasizing the role and need of 2-[18F]-FDG PET/CT in oncology.
Dr. Domenico Albano
Prof. Francesco Bertagna
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- nuclear medicine